Healthcare Realty Trust
HR · Health Care REITs
$17.95
0.1%Sabra Health Care REIT
SBRA · Health Care REITs
$19.56
0.2%The short version
- Healthcare Realty Trust is the larger business, with $1.2B of revenue in fiscal 2025 against $775M for Sabra Health Care REIT, about 1.5 times as much.
- Sabra Health Care REIT grew revenue faster (10.2%, against −6.9%).
| Latest fiscal year | HR · FY25 | SBRA · FY25 |
|---|---|---|
| Size | ||
| Market cap | $6.1B | $4.9B |
| Revenue | $1.2B | $775M |
| Free cash flow | $127M | — |
| Net income | −$246M | $156M |
| Growth | ||
| Revenue growth | −6.9% | 10.2% |
| 5-year growth | 18.8% | 5.3% |
| Share count change | −4.3% | 3.6% |
| Profitability | ||
| Gross margin | — | — |
| Operating margin | — | — |
| Net margin | −20.8% | 20.1% |
| FCF margin | 10.8% | — |
| Return on capital | — | 5.1% |
| Return on equity | −5.0% | 5.6% |
| Balance sheet | ||
| Net debt | $4.0B | $2.5B |
| Net debt / EBITDA | — | 5.4x |
| Dividends and buybacks | $391M | $290M |
| Valuation & quality | ||
| P/E | — | 75.2x |
| Piotroski F-score | — | — |
FY16
HR $461M
SBRA $261M
FY17
HR $614M
SBRA $408M
FY18
HR $696M
SBRA $623M
FY19
HR $692M
SBRA $662M
FY20
HR $500M
SBRA $599M
FY21
HR $535M
SBRA $570M
FY22
HR $933M
SBRA $625M
FY23
HR $1.3B
SBRA $648M
FY24
HR $1.3B
SBRA $703M
FY25
HR $1.2B
SBRA $775M
HR
SBRA
FY16
HR 22.1%
SBRA —
FY17
HR 20.1%
SBRA —
FY18
HR —
SBRA —
FY19
HR —
SBRA —
FY20
HR —
SBRA —
FY21
HR —
SBRA —
FY22
HR —
SBRA —
FY23
HR —
SBRA —
FY24
HR —
SBRA —
FY25
HR —
SBRA —
HR
SBRA
FY16
HR $161M
SBRA —
FY17
HR $243M
SBRA —
FY18
HR $260M
SBRA —
FY19
HR $249M
SBRA —
FY20
HR $395M
SBRA —
FY21
HR $135M
SBRA —
FY22
HR $109M
SBRA —
FY23
HR $269M
SBRA —
FY24
HR $253M
SBRA —
FY25
HR $127M
SBRA —
HR
SBRA
FY16
HR 2.5%
SBRA 5.8%
FY17
HR 2.0%
SBRA 5.8%
FY18
HR —
SBRA 6.8%
FY19
HR —
SBRA 3.2%
FY20
HR —
SBRA 4.4%
FY21
HR —
SBRA 3.1%
FY22
HR —
SBRA 2.1%
FY23
HR —
SBRA 2.2%
FY24
HR —
SBRA 4.7%
FY25
HR —
SBRA 5.1%
HR
SBRA
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.